- Carlyle (CG) confirms that it has agreed to acquire Johnson & Johnson's (JNJ +0.3%) Ortho-Clinical Diagnostics (OCD) business for $4.15B.
- "This transaction is a result of our disciplined approach to portfolio management in order to achieve the greatest value for Johnson & Johnson," J&J CEO Alex Gorsky says.
- OCD provides products for screening, diagnosing, monitoring and confirming diseases, including blood-screening equipment and laboratory blood tests. It's a smallish player in a market led by Roche, Siemens and Abbott Labs. (PR)